Expression of angiogenic factors Cyr61 and tissue factor in uveal melanoma.
OBJECTIVE
To study the expression of angiogenic factors Cyr61 and tissue factor (TF) in uveal melanoma and its correlation with blood vessel density.


METHODS
Suppression subtractive hybridization was used to identify genes that are differentially expressed between cell lines of uveal melanoma and normal uveal melanocytes. Expression of these genes was subsequently verified in primary uveal melanomas and correlated with the number of blood vessels in archival specimens by immunohistochemical analysis.


RESULTS
Cyr61 and TF are expressed at elevated levels in cell lines of uveal melanoma compared with normal uveal melanocytes. Duplication of a region of chromosome arm 1p, encompassing the genes encoding Cyr61 and TF, was observed in the melanoma cell line used in the initial subtractive hybridization. Both genes are also expressed in primary uveal melanomas, and a correlation was found between expression of TF and the number of blood vessels in archival specimens.


CONCLUSIONS
Cyr61 and TF may contribute to the angiogenic phenotype associated with uveal melanoma. A region of chromosome arm 1p also may contain oncogenes or tumor suppressor genes pertinent to the origins of this type of ocular tumor.


CONCLUSIONS
New immunotherapies have been devised for the treatment of cancer based on the expression of TF. Similar approaches may be effective in treating uveal melanoma.
Walker
Teresa M
TM
Department of Ophthalmology and Visual Sciences, University of Wisconsin Medical School, Room K6/466 Clinical Sciences Center, Madison, WI 53792, USA.
Van Ginkel
Paul R
PR
Gee
Ricardo L
RL
Ahmadi
Hoda
H
Subramanian
Lalita
L
Ksander
Bruce R
BR
Meisner
Lorraine F
LF
Albert
Daniel M
DM
Polans
Arthur S
AS
D015153:Blotting, Western; D002878:Chromosomes, Human, Pair 1 / Q000235:genetics; D055515:Cysteine-Rich Protein 61; D003582:Cytogenetics; D016228:Endothelial Growth Factors / Q000378:metabolism; D006801:Humans; D017874:Immediate-Early Proteins / Q000235:genetics* / Q000378:metabolism; D007124:Immunoenzyme Techniques; D017404:In Situ Hybridization, Fluorescence; D036341:Intercellular Signaling Peptides and Proteins / Q000235:genetics* / Q000378:metabolism; D008222:Lymphokines / Q000378:metabolism; D008545:Melanoma / Q000098:blood supply / Q000378:metabolism*; D009389:Neovascularization, Pathologic / Q000473:pathology; D012333:RNA, Messenger / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013925:Thromboplastin / Q000235:genetics* / Q000378:metabolism; D014407:Tumor Cells, Cultured; D014604:Uveal Neoplasms / Q000098:blood supply / Q000378:metabolism*; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
C501848:CCN1 protein, human; D055515:Cysteine-Rich Protein 61; D016228:Endothelial Growth Factors; D017874:Immediate-Early Proteins; D036341:Intercellular Signaling Peptides and Proteins; D008222:Lymphokines; D012333:RNA, Messenger; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D013925:Thromboplastin